NCT07949760
WOKVAC Vaccine to Prevent Brain Metastases in Metastatic HER2 Positive Breast Cancer, SHIELD Trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Secondary (3)
Arms and interventions
Patients receive WOKVAC mixed with sargramostim ID at months 1, 2, 3, 6, 12, and 24 in the absence of brain metastases or unacceptable toxicity. Patients may also receive tetanus-diptheria immunization with first vaccine per standard of care. Additionally, patients undergo blood sample collection and magnetic resonance imaging (MRI) or computed tomography (CT) at baseline and possibly at later study milestones.
Biologicals: pUMVC3-IGFBP2-HER2-IGF1R Plasmid DNA Vaccine, Sargramostim, Tetanus and Diphtheria Toxoids Adsorbed
Procedures: Computed Tomography, Magnetic Resonance Imaging, Biospecimen Collection
Sites
1 site in 1 country
- Fred Hutch/University of Washington Cancer ConsortiumSeattle, Washington, United States